English

news

2018
News:
Jan. 29th, Melinta Therapeutics Launches Baxdela (Delafloxacin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the United States.

Publication:
Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance
Hirano, T.; Kinoshita, T.; Kazamori, D.; Inoue, S.; Nishimura, K.; Sakurai, A.; Ohishi, K.; Kuramoto, Y.; Amano, H.; Yazaki, A. Chem. Pharm. Bull. 2018, 66, 235 - 238.

2017
News:
June 19th, Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Poster Presentation:
June 3rd, ASM microbe 2017 (New Orleans, USA)
Structure-Activity Relationships of Novel Fluoroquinolone Antibiotics,
WFQ-101 and its Derivatives, Containing 2-Hydroxymethylphenyl Group at N-1 Position
Kinoshita, T.; Kazamori, D.; Inoue, S.; Nishimura, K.; Hirano, T.; Sakurai, A.; Sasaki, A.; Arai, M.; Kuramoto, Y.; and Yazaki, A.

Poster Presentation:
June 3rd, ASM microbe 2017 (New Orleans, USA)
Pharmacodynamics of WFQ-253, a Novel Fluoroquinolone, in Murine
Pneumonia Model of P. aeruginosa Infection
Kazamori, D.; Kinoshita, T.; Sasaki, A.; Nishida, M.; Oishi, K.; Inoue, S.;
Hirano, T.; Kuramoto, Y.; and Amano, H.

Poster Presentation:
Apr. 5th, AACR ANNUAL MEETING 2017 (Washinton, USA)
In vitro and in vivo evaluation of WAC-224, a novel quinolone class of topoisomerase II inhibitor for cancer therapy
Ueshima, T.; Yamaguchi, T.; Itoh, K.; Kashimoto, N.; Kazamori, D.; Hirano, T.; Shimabara, R.; Kawakubo, Y.; Sato, M.; Yamashita, J.; Yazaki, A.; and Tamura, K.

2016
Poster Presentation:
June 19th, ASM microbe 2016.(Boston, USA)
Identification of Novel Fluoroquinolones, WFQ-101 And Its Analogues, Circumventing Bacterial Efflux Pumps.
Kazamori, D.; Kinoshita, T.; Sasaki, A.; Inoue, S.; Hirano, T.; Amano, H.; Kuramoto, Y.; Yazaki, A.


News:
Oct. 24th. MELINTA THERAPEUTICS submits BAXDELA (Delafloxacin) new drug applicationfor hospital-treated skin infections

2015
Publication:
Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoroquinolones a orally active antibacterial agents
Itoh, K.; Kuramoto, Y.; Amano, H.; Kazamori D.; Yazaki, A. Eur. J. Med. Chem. 2015, 103, 354 - 60.

News:
July 23rd
Zerbaxa was approved by the EMA.